RecruitingPhase 2NCT05814055

The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence


Sponsor

University of Florida

Enrollment

76 participants

Start Date

Jun 6, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study will evaluate the compliance with a daily kava regimen among active smokers who have an intention to quit smoking. This study will also investigate whether kava use can facilitate tobacco cessation, reduce stress, and improve sleep.


Eligibility

Min Age: 21 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AB-free kava and a drug called Placebo for people with smoking. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPlacebo

Participants on this arm will take one placebo capsule orally three times daily for 4 weeks.

DRUGAB-free kava

Participants on this arm will take one kava capsule (each capsule contains 75 mg of kavalactones) orally three times daily for 4 weeks.


Locations(1)

University of Florida

Gainesville, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05814055


Related Trials